CorMedix swings to Q3 2026 net loss of $14.72 million
CRMD•CRMD•CRMD•CRMD•CorMedix reported a third-quarter 2026 net loss of $14.7 million, compared with net income of $108.6 million a year earlier, as revenue fell 48% to $54.5 million. It maintained 2026 revenue guidance of $325 million to $345 million and suspended its 2027 DefenCath revenue guidance.
CorMedix swung to a third-quarter 2026 net loss of $14.7 million from net income of $108.6 million a year earlier. Consolidated revenue declined 48% year over year to $54.5 million, with DefenCath sales falling largely because of lower post-TDAPA pricing.
CorMedix maintained full-year 2026 consolidated revenue guidance of $325 million to $345 million. It suspended previously issued 2027 DefenCath revenue guidance following recently announced CMS reimbursement framework changes. The pending acquisition of substantially all Heron Therapeutics assets is expected to close in the first quarter of 2027.
